Core Viewpoint - Myriad Genetics, Inc. is under investigation following the announcement that UnitedHealth Group will cease coverage of its GeneSight genetic test, leading to a significant drop in Myriad's stock price [2]. Group 1: Investigation Details - On October 31, 2024, UnitedHealth Group announced it would no longer cover GeneSight, effective January 1, 2025, citing that tests for behavioral health, including GeneSight, are "unproven" and "not medically necessary" [2]. - Following this announcement, Myriad's stock price experienced a sharp decline during intraday trading on November 1, 2024 [2]. Group 2: Legal Representation - Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad securities and encourages affected investors to participate in the investigation [1][3]. - The firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful in court [3]. Group 3: Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [4].

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad’s GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025. After initial review of the updated policy, the company strongly disagrees with UnitedHealth ...

SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2024. A live webcast of the earnings conferenc ...

Myriad Genetics, Inc. (MYGN) has announced a strategic partnership with jscreen, a national organization focused on genetic education and preventative testing for high-risk populations.This collaboration merges Myriad’s advanced hereditary cancer and reproductive genetic products, MyRisk with RiskScore and Foresight Carrier Screen, with jscreen’s well-established education and care navigation platform. Through this alliance, the organizations aim to reach hundreds of thousands of individuals across the Unit ...

Myriad Genetics, Inc. (MYGN) recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics.Myriad Genetics has purchased a new UG 100 platform that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco. The low-cost, low-error sequencing achievable on the ...

SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad’s Precise® MRD test. Research collaborations include: A study to determine whether circulating tumor DNA (ctDNA) level may predict magnitude of response to pembrolizumab and hormonal therapy in patients with HR-positive ...

Core Insights - Myriad Genetics and Ultima Genomics have announced a collaboration to utilize Ultima's UG 100™ sequencing platform and ppmSeq™ technology to enhance Myriad's clinical testing capabilities [1][2][3] Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health through genetic insights that improve patient care and reduce healthcare costs [4] - Ultima Genomics aims to revolutionize genomic sequencing by providing low-cost, high-throughput sequencing solutions that can scale beyond conventional technologies [5] Technological Advancements - The UG 100 platform is expected to provide low-cost and low-error sequencing, which will benefit Myriad's emerging products, particularly the Precise Molecular Residual Disease (MRD) test and the FirstGene Multiple Prenatal Screen [2][3] - Myriad's Precise MRD test will utilize whole-genome sequencing to identify tumor-specific variants, enhancing personalized tracking for cancer patients [2] - The FirstGene Multiple Prenatal Screen will streamline multiple prenatal tests into a single sequencing workflow, requiring deep and accurate sequencing capabilities [2] Strategic Goals - Myriad's collaboration with Ultima is aimed at making cutting-edge genetic testing more accessible and affordable, with the UG 100 potentially lowering costs and improving quality for their tests [3] - The partnership is expected to facilitate the exploration of new product areas that may have been previously challenging due to high sequencing costs [3]

SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent no. 12,104,212, entitled “Personalized Methods for Detecting Circulating Tumor DNA,” demonstrates Myriad’s continued efforts to advance ...

Myriad Genetics, Inc. (MYGN) is making notable strides in its key strategic areas, which is poised to help it grow in the upcoming quarters. New product introductions and enhancements are gaining traction with customers. There is growing optimism about the company’s huge potential in the oncology space. Meanwhile, the impacts of macroeconomic pressure and fierce rivalry can be worrisome for Myriad Genetics’ performance.In the past year, this Zacks Rank #3 (Hold) company has outperformed both the industry an ...

Myriad Genetics (MYGN) has been gaining share in the hereditary cancer market, with volumes rising 3% year over year in the second quarter of 2024. The company continues to see momentum in its prenatal business as well, growing 25% year over year with a 12% increase in testing volume. This volume growth reflects ongoing initiatives to improve average selling prices (ASPs). The stock carries a Zacks Rank #3 (Hold) currently.The company continues to enhance its customer targeting, digital marketing, and overa ...